培米替尼最新公布价格表

Pemetinib is a targeted drug used to treat cholangiocarcinoma, especially for patients with FGFR2 gene fusion or rearrangement. This article will conduct a detailed analysis of the latest price of pemetinib, drug preparation quantity, and medication for special groups to help patients better understand the economics and usage of the drug.

The latest announced price of pemetinib

The original drug has been launched in China. Its price varies with different specifications and is for reference only. It is currently understood that the price of a box of 9mg*14 pills is about US$5,781, and the price of a box of 4.5mg*14 pills is about US$3,400. This price reflects the R&D costs and market positioning of pemetinib as an innovative drug.

Factors affecting price

The price of pemetinib is affected by a variety of factors, including research and development costs, production processes, market demand and patent protection. As a targeted drug, the development process of pemetinib is complex and costly, which directly affects its market price. In addition, market demand and patent protection are also important factors in determining price.

Although the price of pemetinib is relatively high, it is highly effective in treating patients with cholangiocarcinoma with specific gene mutations. Patients can choose according to their own financial situation and treatment needs.

Quantity of pemetinib preparation

The quantity of pemetinib preparation needs to be adjusted according to the patient’s treatment cycle and dosage. Normally, patients take 13.5 mg orally once a day for 14 consecutive days, and then stop taking the drug for 7 days, and every 21 days constitutes a treatment cycle.

Calculation of treatment cycle

Based on a once-daily dose of 13.5 mg, the patient needs to take 14 tablets of 9 mg every 21 days. Therefore, each box of 9mg*14 pills can meet the needs of one treatment cycle. For the 4.5mg strength drug, patients need to take 28 tablets every 21 days, that is, two boxes of 4.5mg*14 tablets.

Medicine preparation suggestions

In order to ensure the continuity of treatment, it is recommended that patients prepare medicines in advance according to the doctor's prescription and treatment plan. Typically, patients can prepare 2-3 treatment cycles of the drug to account for possible treatment extensions or dose adjustments. In addition, patients should communicate with their doctors regularly and adjust the quantity of medicines prepared in a timely manner according to changes in condition.

The number of pemetinib preparations needs to be adjusted according to the patient's treatment cycle and dosage. It is recommended that patients prepare the medicine in advance according to the doctor's prescription and treatment plan.

Usage of pemetinib in special groups

The use of pemetinib in special groups requires special attention, including liver function impairment, renal function impairment, elderly patients, and children.

Patients with hepatic impairment

For patients with severe hepatic impairment (total bilirubin >3×ULN with any AST), the recommended starting dose is 9 mg. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Patients should monitor liver function regularly during treatment.

Patients with renal impairment

For patients with severe renal impairment (eGFR 15~29 mL/min/1.73m²), the recommended starting dose is 9 mg. No dosage adjustment is necessary in patients with mild or moderate renal impairment. No dose adjustment is also required in patients with end-stage renal disease receiving intermittent hemodialysis. Patients should have their kidney function monitored regularly during treatment.

Elderly patients and pediatric patients

The application data of pemetinib in elderly patients is limited. It is recommended to use it with caution under the guidance of a doctor, without adjusting the starting dose. For pediatric patients under 18 years of age, the safety and effectiveness of pemetinib have not been established and its use is not recommended.

The use of pemetinib in special groups requires special attention, and patients should make adjustments under the guidance of their doctors according to their own conditions.